Latest news with #JBChemicals&Pharmaceuticals
Business Standard
a day ago
- Business
- Business Standard
JB Chemicals Q1 PAT jumps 14% YoY to Rs 202 cr
JB Chemicals & Pharmaceuticals reported consolidated net profit surged 14.45% to Rs 202.38 crore on an 8.91% jump in revenue from operations to Rs 1,093.94 crore in Q1 FY26 over Q1 FY25. Profit before tax (PBT) stood at Rs 271.61 crore in Q1 FY26, rising 13.25% from the Rs 239.84 crore recorded in Q1 FY25. In Q1 FY26, operating EBITDA stood at Rs 330 crore, up 13%, compared with Rs 292 crore posted in the same quarter last year. Operating EBITDA margin stood at 30.2% in Q1 FY26 as against 29% in Q1 FY25. Nikhil Chopra, CEO and whole-time director of JB Pharma, stated, JB continues to be the fastest-growing domestic pharma company amongst the top 25 organizations as per IQVIA MAT Jun25 data. The domestic business recorded approximately 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands & their franchises are also performing well. The CDMO business momentum is likely to be sustained in coming quarters. Our operating EBITDA margins crossed 30% for the first time, which highlights the results of our strategy of focusing on profitable growth. Going forward, we will maintain focus on driving topline growth, cost optimization, and organizational efficiencies. I am confident that the organization will continue to perform well, with our domestic and CDMO segments leading the way on growth and profitability. We have all the necessary building blocks in place for sustainable growth in the coming years. JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radiodiagnostics, APIs, and intermediates. Shares of JB Chemicals & Pharmaceuticals fell 1.67% to Rs 1,753.15 on the BSE.
Business Standard
a day ago
- Business
- Business Standard
J B Chemicals & Pharmaceuticals consolidated net profit rises 14.45% in the June 2025 quarter
Sales rise 8.91% to Rs 1093.94 croreNet profit of J B Chemicals & Pharmaceuticals rose 14.45% to Rs 202.38 crore in the quarter ended June 2025 as against Rs 176.83 crore during the previous quarter ended June 2024. Sales rose 8.91% to Rs 1093.94 crore in the quarter ended June 2025 as against Rs 1004.40 crore during the previous quarter ended June EndedJun. 2025Jun. 2024% 9 OPM %27.5027.91 -PBDT314.31280.62 12 PBT271.61239.84 13 NP202.38176.83 14 Powered by Capital Market - Live News
Hans India
2 days ago
- Business
- Hans India
2 deals put India on top-10 Apac M&A list
New Delhi: Mergers and Acquisition (M&A) activity in Asia-Pacific region fluctuated throughout the year, declining in June as dealmakers awaited clarity to emerge on global trade negotiations, a report said on Tuesday. Meanwhile, the $1.39 billion acquisition of a minority stake in JB Chemicals & Pharmaceuticals by Torrent Pharmaceuticals in India was June's third-largest Asia Pacific deal, according to S&P Global Market Intelligence data. Two of India's deals made it to the list of the top-10 largest deals in June. The aggregate value of M&A deals in the Asia Pacific region declined 21.3 per cent YoY to $28.87 billion in June. However, the number of deals increased 13.2 per cent to 834. The decline came after a 57.4 per cent jump in May. On a month-over-month basis, the aggregate deal value fell 32.1 per cent in June, while the number of deals was up 12.2 per cent. The report said that 28 per cent of Asian respondents were more interested in M&A due to trade concerns. 'Asian dealmakers are adapting rather than retreating from deals. This was the highest positive response of any international region, indicating that many sAsian companies viewed the disruption as a chance, for example, to pursue non-US targets,' the report mentioned. According to the report, local private equity firms are eager to deploy funds in midmarket deals in Southeast Asia, while larger international funds are shopping for bigger targets in East Asia. 'Many respondents see private equity buyers as key acquirers across Asia.' These include private equity deals and growth investments, such as buyouts of family businesses in Southeast Asia, carve-outs in Japan or growth equity in Indian technology startups, the report said. US President Donald Trump's April announcements of 'reciprocal tariffs' in April shook global markets. On July 23, the US and Japan reached a deal that includes 15 per cent tariffs on Japanese imports into US.
Time of India
29-06-2025
- Business
- Time of India
Torrent Pharma to acquire JB Chem for over Rs 25,000 crore
NEW DELHI: Ahmedabad-based Torrent Pharma will acquire a controlling stake in JB Chemicals & Pharmaceuticals (JB Chem) from PE major KKR for an equity valuation of Rs 25,689 crore. The transaction will be executed in two phases.
Time of India
29-06-2025
- Business
- Time of India
Torrent, JB Chem Finalising Steps for Two-stage Merger
Synopsis Torrent Pharmaceuticals and JB Chemicals & Pharmaceuticals are working with advisers to firm up the terms for their merger as part of a two-stage transaction, involving the former first buying out US-based private equity firm KKR's stake in JB in a cash deal, said people familiar with the development.
